1 / 8

ASEAN and China Biosimilars Market Business Status and Outlook 2017 – 2025

Indonesia generated the highest revenue in the ASEAN biosimilars market in 2017 and is expected to remain dominant throughout the forecast period. Based on molecule type, the erythropoietin segment accounted for the second highest share in the ASEAN and China biosimilars market in 2017 and is expected to maintain this trend throughout the forecast period. Based on application, the blood disorders segment is estimated to rank second in terms of revenue in both, the ASEAN, and the China biosimilars market throughout the analysis period. The diabetes segment generated the highest CAGR from 2018 to 2025 in the ASEAN and China biosimilars market.<br>

allied123
Download Presentation

ASEAN and China Biosimilars Market Business Status and Outlook 2017 – 2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASEAN and China Biosimilars Market Dynamics and Trends, Efficiencies Forecast 2023 Opportunity Analysis and Industry Forecast, 2016-2023 Global Opportunity Analysis and Industry Forecast, 2017-2025

  2. Biosimilars Market Overview China is projected to offer business expansion opportunities for biosimilars owing to its large population and centralized healthcare policies. This has propelled the government to offer numerous opportunities for the expansion of the biosimilars market across China. In addition, heavy investment by key players in ASEAN countries to increase the accessibility of biosimilars drives the market growth.

  3. Biosimilars Market According to a new report published by Allied Market Research, titled,"ASEAN and China Biosimilars Market by Molecule Type, and Application: Opportunity Analysis and Industry Forecast, 2018 - 2025,"the ASEAN and China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Access Full Summary at: https://www.alliedmarketresearch.com/asean-and-china- biosimilars-market Biosimilars are replicas of biologic drugs that are approved by the concerned regulatory authorities for use in the treatment of several medical indications. According to the U.S. law, a biosimilar is approved based on its similarity to the FDA- approved biological product, also known as the reference product.

  4. Biosimilars Market Driving Factor The key driving factors of the ASEAN and China biosimilars market include rise in the number of blockbuster drugs whose patents would be expiring along with high prevalence of chronic diseases among the ageing population across the ASEAN countries and China. In addition, lower cost of biosimilars drugs than original biologics has fueled the market growth. However, high initial investment in R&D is anticipated to hamper the growth of the market. Moreover, increased focus of the international key players to invest in untapped economies of the ASEAN region and China offers lucrative opportunities for expansion of the biosimilars market.

  5. Biosimilars Market Key Players • • • • • • • • • 3SBIO Inc Qilu Pharmaceutical Novartis International AG (Sandoz International GmBH) Pfizer Inc. (Hospira) STADA Arzneimittel Beijing SL Pharmaceutical Co. Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.) Amgen Inc AstraZeneca Plc

  6. Biosimilars Market Key Segments By Molecule Type • • • • • • • Human Growth Hormone Erythropoietin Monoclonal Antibody Insulin Interferon Granulocyte-Colony Stimulating Factor Peptide By Application • • • • • Blood Disorders Oncology Diseases Chronic and Autoimmune Diseases Growth Hormone Deficiency Others

  7. Biosimilars Market by Region 1. China 2. ASEAN Region • Singapore • Malaysia • Thailand • Indonesia • Philippines • Vietnam • Rest of ASEAN Countries

  8. Biosimilars Market Thank You! For More Details Visit us at https://www.alliedmarketresearch.com/request- sample/5080 Follow Us On

More Related